weave
person
press
In recent years, the guidelines and consensus on chronic hepatitis B have been continuously updated, and the antiviral treatment population has been expanded, and the clinical cure of hepatitis B has received wider attention and recognition. The evidence-based medical evidence of clinical cure of chronic hepatitis B has been gradually enriched and improved, and the exploration of clinical cure and related scientific issues in different types of hepatitis B population has become a research hotspot. The "Chronic Hepatitis B Clinical Cure Summit and China Summit Forum" has been successfully held for five sessions, witnessing the rapid development of clinical cure of chronic hepatitis B and rich clinical practice from "pilot road" to "new chapter", "new future", "new journey", and then to "new dream".
Sharing cutting-edge progress and promoting field exchanges - the "6th Academic Conference on Clinical Cure of Chronic Hepatitis B", focusing on the clinical cure of chronic hepatitis B, will be grandly opened in Xiamen, Fujian Province on May 18! "Gather Chinese wisdom and draw a new blueprint for clinical cure of chronic hepatitis B". We sincerely invite you to the academic feast and share the latest achievements and concepts of clinical cure of chronic hepatitis B!
Morning – Main Venue
Theme 1
Prospects for the treatment of clinical cure of chronic HBV infection
At present, the level of evidence-based medical evidence for clinical cure of chronic hepatitis B has been improved, especially for the nucleoside treatment population, the evidence of clinical cure in the inactive HBsAg carrier population and children with chronic hepatitis B is more abundant, and the clinical cure research of more people is also being actively explored and expanded. Various biological indicators and models for predicting clinical cure of hepatitis B have been deepened. What other scientific questions are worth exploring around the clinical cure of hepatitis B? How durable is a clinical cure for hepatitis B? What is the effect of retreatment in patients with relapse? What is the clinical cure and durability of new hepatitis B drugs? Will cccDNA, integrated HBV DNA, and intrahepatic HBsAg also be cleared after clinical cure? Professor Wang Guiqiang will systematically and comprehensively share the "Prospects for the Treatment of Clinical Cure of Chronic HBV Infection" around these new developments.
Theme 2
Exploration of chronic hepatitis B treatment strategies with the ultimate goal of preventing liver cancer
Most liver cancers in mainland China are caused by HBV, and the prognosis of liver cancer is poor and the survival rate is low, so the ultimate goal of HBV treatment is to prevent the occurrence of liver cancer and prolong the survival of patients. A large number of studies have confirmed that active antiviral therapy can effectively prevent the occurrence of liver cancer. How to further optimize antiviral therapy strategies to minimize the risk of liver cancer in patients with chronic hepatitis B? What are the results of the Oasis Project and the Paradise Study for Liver Cancer Prevention? Can patients with chronic hepatitis B have the dual benefits of clinical cure and prevention of liver cancer? Professor Xie Qing will share with us a comprehensive "Exploration of Chronic Hepatitis B Treatment Strategies with the Ultimate Goal of Preventing Liver Cancer".
Theme three
Clinical cure of chronic hepatitis B in children and expert consensus
With the deepening of the clinical cure of hepatitis B, the diagnosis and treatment of chronic hepatitis B in children has attracted more attention and attention. The 2022 guidelines in mainland China expand the indications for antiviral therapy in children with hepatitis B, and the "Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children" was officially released in mainland China not long ago, which will further standardize the diagnosis and treatment of chronic hepatitis B in children. Academician Wang Fusheng will systematically explain the "Clinical Cure and Expert Consensus of Chronic Hepatitis B in Children".
Theme 4
Exploration of innovative specialized outpatient clinics in the field of clinical cure of hepatitis B
In order to further standardize the diagnosis and treatment mode of hepatitis B and improve the clinical cure skills of doctors, the "Standardized Construction and Capacity Improvement Project of Hepatitis B Clinical Cure Outpatient Clinic" initiated by the Hospital Management Institute of the National Health Commission was launched in November 2023 to help more patients achieve clinical cure by providing a new model of hepatitis B diagnosis and treatment of "scientific management of the whole course of the disease" and individualized diagnosis and treatment plans. At present, a number of "hepatitis B clinical cure clinics" have been set up across the country, and Professor Gao Zhiliang will share with us "Exploration of Innovative Specialized Disease Clinics in the Field of Clinical Cure of Hepatitis B".
Theme 5
How hepatitis B vaccine can help patients with clinical cures turn HBsAb to positive
Previous studies have shown that the persistence of clinical cure of hepatitis B is good, and sufficient consolidation treatment time and high level of HBsAb are conducive to the improvement of persistence. Differing views remain on the use of hepatitis B vaccine in clinical cure of hepatitis B. Studies have shown that hepatitis B vaccination in HBsAb-negative patients after clinical cure can promote HBsAb conversion and its level, and its role in the durability of clinical cure is still worthy of further exploration. Professor Chen Xinyue will introduce to us "How Hepatitis B Vaccine Helps Clinically Cured Patients to Turn HBsAb to Positive".
Eliminate hepatitis B, we're on the move
At present, the burden of hepatitis B in mainland China is still relatively severe, and to achieve the ambitious goal of eliminating hepatitis B, it is necessary for the government, medical institutions, enterprises and other parties to work together. How to effectively prevent and treat viral hepatitis, all provinces have formulated targeted strategies. The meeting will be chaired by Li Zengde, Secretary-General of the China Foundation for Hepatitis Prevention and Control, and experts from Hainan Province, Fujian Province and Guangdong Province will explain in detail the strategies and progress of hepatitis prevention and control in each province, and share the experience of the pilot project.
Coping with Chronic Hepatitis B: Situation, Philosophy, Hope
The World Health Organization has proposed that by 2030, the diagnosis rate of hepatitis B should be increased to 90%, and the treatment rate should be increased to 80%, but the current diagnosis rate of hepatitis B in mainland China is only 24%, and the treatment rate is only 15%, and patients' awareness of hepatitis B and clinical cure of hepatitis B is still low. What is the current status of chronic hepatitis B prevention and treatment in mainland China? How to effectively change patients' perceptions and better communicate health? Where is the hope for chronic hepatitis B treatment? Prof. Xiao Li from the China Health Education Center will moderate a unique popular science dialogue, and Wang Junping, Deputy Editor-in-Chief of the People's Daily Health Client, Luo Gang, Executive Director and Deputy Secretary-General of the China Association for Health Promotion and Education, and Prof. Ning Qin, Prof. Wan Mobin and Prof. Xie Yao, clinical experts in liver disease, will have an in-depth discussion with us.
Round Table Pie
From early exploration to concept proposal, and then to domestic and international recognition, the clinical cure of chronic hepatitis B has entered a stage of comprehensive and in-depth exploration, evidence-based medical evidence has been upgraded, and a number of projects related to clinical cure of hepatitis B for different populations are in full swing. Professor Lin Bingliang will be invited to chair the roundtable discussion session, and Professor Dang Shuangsuo, Professor Geng Jiawei, Professor Jiang Jiaji, Professor Li Minghui, Professor Shang Jia and Professor Song Jianxin will share their experiences on the projects related to the clinical cure of hepatitis B, and discuss the scientific issues that are still worth studying in the clinical cure of chronic hepatitis B.
Afternoon – Session 1
HBsAg Low-level Treatment-Emergent Dominant Population Clinical Cure Forum - Starlight Program Annual Meeting
The 2022 hepatitis B guidelines in mainland China updated the definition of people with inactive HBsAg carrier status, but the study found that the clinical cure rate of treatment-naïve hepatitis B people with low HBsAg levels was higher, and they were all the dominant groups for clinical cure of hepatitis B. The "Hepatitis B Clinical Cure Starlight Project" was initiated and established by the Liver Health Promotion Center of Zoomlion, and Beijing You'an Hospital affiliated to Capital Medical University and the Third Affiliated Hospital of Sun Yat-sen University jointly undertook technical guidance, aiming to explore the clinical cure of patients with HBeAg-negative chronic HBV infection. This conference will bring the latest progress and phased research results of the Starlight Project, and conduct in-depth discussions on clinical hot issues. In addition, the promotion of the new specialized outpatient clinic for clinical cure of hepatitis B will further promote the development of hepatitis B prevention and treatment in China.
Afternoon – Session 2
Practical experience sharing of clinical cure
The research and clinical practice of clinical cure for hepatitis B dominant populations have been abundant, but the clinical cure for non-dominant populations and special populations is still in the stage of continuous optimization and exploration. A number of experienced clinical experts will share their treatment strategies and management experience for nucleoside-experienced patients, inactive HBsAg carriers, children with hepatitis B, and non-dominant populations. How to communicate with patients from the perspective of clinical cure and long-term prognosis? How to properly deal with adverse effects of interferon? This experience exchange will jointly help improve the clinical cure skills of hepatitis B.
Afternoon – Session 3
Forum on Complex Liver Disease
For the difficulties and thorny problems in the treatment of chronic hepatitis B, the conference will invite a number of experts to conduct in-depth analysis and discussion, focusing on the disease progression and treatment strategies of patients with hepatitis B cirrhosis, patients in the immunotolerant stage of chronic hepatitis B and patients with chronic hepatitis B combined with other diseases, the impact of antiviral therapy on the integration of HBV DNA, the research status of immunotherapy for chronic hepatitis B, and the special performance of serum markers in the treatment of chronic hepatitis B.
Source: Yulu Liver Lin